Zacks Investment Research downgraded Kura Oncology Inc (NASDAQ:KURA) to Sell in a report released today.
- Updated: September 19, 2016
Zacks Investment Research has downgraded Kura Oncology Inc(NASDAQ:KURA) to Sell in a report released on 9/20/2016.
Yesterday Kura Oncology Inc (NASDAQ:KURA) traded 0.72% higher at $6.99. The company’s 50-day moving average is $5.36 and its two hundred day average is $3.93. The last stock close is up 78.09% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. Trade volume was down over the average, with 166,421 shares of KURA changing hands under the typical 323,609 shares..
Recent Performance Graph:
Kura Oncology Inc has a 52 week low of $2.50 and a one-year high of $25.00 and has a total market value of $0.0.
Also covering Kura Oncology Inc’s price target, a total of 4 analysts have issued a report on the stock. The one year target is $18.00 with 0 rating the stock a strong buy, 0 rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and lastly 0 analystsrating the stock as sell.
About Kura Oncology Inc (NASDAQ:KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer (NSCLC) and melanoma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.